[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 429
Citations 0
Observation
October 2015

Memantine-Associated Corneal Endothelial Dysfunction

Author Affiliations
  • 1Price Vision Group, Indianapolis, Indiana
  • 2Cornea Research Foundation of America, Indianapolis, Indiana
JAMA Ophthalmol. 2015;133(10):1218-1220. doi:10.1001/jamaophthalmol.2015.2476

Alzheimer disease (AD) is the most common type of dementia and a growing public health concern. Its estimated prevalence in the United States is 5.2 million cases and is projected to exceed 13 million cases by 2050.1 With no cure available, therapy is palliative via modulation of acetylcholine and glutamate. Current treatment patterns favor cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists, respectively.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×